BCM
IMMU

BlueCrest Capital Management’s Immunomedics Inc IMMU Stock Holding History

BlueCrest Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-41,500
Closed -$96K – 1063
2016
Q2 		$96K Buy
+41,500
New +$139K ﹤0.01% 826

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlueCrest Capital Management's IMMU Position: Q3 2018 in Review

BlueCrest Capital Management sold out of Immunomedics Inc (IMMU) in Q3 2018, closing a stake of 19,400 shares — an estimated $459K sold.

BlueCrest Capital Management first reported a position in IMMU in Q2 2018 and held it in 1 quarter. The position peaked at $459K in Q2 2018. 207 funds tracked by Wall St. Rank hold IMMU as of Q3 2018.

  • BlueCrest Capital Management reported no remaining Immunomedics Inc position as of Q3 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 19,400 Immunomedics Inc shares in Q3 2018, an estimated $459K.
  • BlueCrest Capital Management first reported a position in Immunomedics Inc in Q2 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Immunomedics Inc position peaked at $459K in Q2 2018.
  • 207 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.